Reactivity patterns and epitope specificities of anti-Cryptococcus neoformans monoclonal antibodies by enzyme-linked immunosorbent assay and dot enzyme assay

Infection and Immunity

Volumn 65, Issue 2, 1997, Pages 718-728

  Belay, Tesfaye ^a   Cherniak, Robert ^a   Kozel, Thomas R ^b   Casadevall, Arturo ^c  

^a GEORGIA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; FUNGUS ANTIBODY; GLYCOSIDE; MANNAN; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; POLYSACCHARIDE;

ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; NONHUMAN; PRIORITY JOURNAL; SEROTYPE;

EID: 0031034049     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.65.2.718-728.1997     Document Type: Article

References (54)

1. Belay, T., and R. Cherniak. 1995. Determination of antigen binding specificities of Cryptococcus neoformans factor sera by enzyme-linked immunosorbent assay. Infect. Immun. 63:1810-1819.
2. Belay, T., and R. Cherniak. 1996. Serotyping of Cryptococcus neoformans by DOT enzyme assay. J. Clin. Microbiol. 34:466-470.
3. Belay, T., R. Cherniak, and T. Shinoda. 1993. Specificity of Cryptococcus neoformans factor sera determined by enzyme-linked immunosorbent assay and dot enzyme assay. Infect. Immun. 61:2879-2885.
4. Bhattacharjee, A. K., J. E. Bennett, and C. P. J. Glaudemans. 1984. Capsular polysaccharides of Cryptococcus neoformans. Rev. Infect. Dis. 6:619-624.
5. Bottone, E. J., I. F. Salkin, N. J. Hurd, and G. P. Wormser. 1987. Serogroup distribution of Cryptococcus neoformans in patients with AIDS. J. Infect. Dis. 156:242.
6. Bulmer, G. S., and M. D. Sans. 1968. Cryptococcus neoformans. III. Inhibition of phagocytosis. J. Bacteriol. 95:5-8.
7. Casadevall, A., M. DeShaw, M. Fan, F. Dromer, T. R. Kozel, and L. Pirofski. 1994. Molecular and idiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxylomannan. Infect. Immun. 62:3864-3872.
8. Casadevall, A., J. Mukherjee, S. J. N. Devi, R. Schneerson, J. B. Robbins, and M. D. Scharff. 1992. Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J. Infect. Dis. 165:1086-1093.
9. Casadevall, A., J. Mukherjee, and M. D. Scharff. 1992. Monoclonal antibody based ELISAs for cryptococcal polysaccharide. J. Immunol. Methods 154: 27-35.
10. Casadevall, A., and M. D. Scharff. 1991. The mouse antibody response to infection with Cryptococcus neoformans: VH and VL usage in polysaccharide binding antibodies. J. Exp. Med. 174:151-160.
11. Cherniak, R., M. M. Cheeseman, G. H. Reyes, E. Reiss, and F. Todaro. 1988. Enhanced binding of capsular polysaccharides of Cryptococcus neoformans to polystyrene microtitration plates for enzyme-linked immunosorbent assay. Diagn. Clin. Immunol. 5:344-348.
12. Cherniak, R., R. G. Jones, and M. E. Slodki. 1988. Type-specific polysaccharides of Cryptococcus neoformans. N.M.R.-spectral study of a glucuronomannan chemically derived from a Tremella mesenterica exopolysaccharide. Carbohydr. Res. 182:227-239.
13. Cherniak, R., L. C. Morris, B. C. Anderson, and S. A. Meyer. 1991. Facilitated isolation, purification, and analysis of glucuronoxylomannan of Cryptococcus neoformans. Infect. Immun. 59:59-64.
14. Cherniak, R., L. C. Morris, S. A. Meyer, and T. B. Mitchell. 1992. Glucuronoxylomannan of Cryptococcus neoformans obtained from patients with AIDS. Carbohydr. Res. 249:405-413.
15. Cherniak, R., L. C. Morris, and S. A. Meyer. 1992. Glucuronoxylomannan of Cryptococcus neoformans serotype C: structural analysis by gas-liquid chromatography-mass spectrometry and by 13C-nuclear magnetic resonance spectroscopy. Carbohydr. Res. 225:331-337.
16. Cherniak, R., and J. B. Sundstrom. 1994. Polysaccharide antigens of the capsule of Cryptococcus neoformans. Infect. Immun. 62:1507-1512.
17. Devi, S. J. N., R. Schneerson, W. Egan, T. J. Ulrich, D. Bryla, J. B. Robbins, and J. E. Bennett. 1991. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infect. Immun. 59:3700-3707.
18. Diamond, R. D. 1995. Cryptococcus neoformans, p. 2331-2340. In G. L. Mandell, J. E. Bennett, and R. G. Douglas, Jr. (ed.), Principles and practice of infectious diseases. Churchill Livingstone, New York, N.Y.
19. Dong, Z. M., and J. W. Murphy. 1995. Intravascular cryptococcal culture nitrate (CneF) and its major component, glucuronoxylomannan, are potent inhibitors of leukocyte accumulation. Infect. Immun. 63:770-778.
20. Dong, Z. M., and J. W. Murphy. 1996. Cryptococcal polysaccharides induce L-selectin shedding and tumor necrosis factor receptor loss from the surface of human neutrophils. J. Clin. Invest. 97:689-698.
21. Dromer, F., and J. Charreire. 1991. Improved amphotericin B activity by a monoclonal anti-Cryptococcus neoformans antibody: study during murine cryptococcosis and mechanisms of action. J. Infect. Dis. 63:1114-1120.
22. Dromer, F., J. Charreire, A. Contrepois, C. Carbon, and P. Yeni. 1987. Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody. Infect. Immun. 55:749-752.
23. Dromer, F., E. Gueho, O. Ronin, and B. Dupont. 1993. Serotyping of Cryptococcus neoformans by using a monoclonal antibody specific for capsular polysaccharide. J. Clin. Microbiol. 31:359-363.
24. Dromer, F., J. Salamero, A. Contrepois, C. Carbon, and P. Yeni. 1987. Production, characterization, and antibody specificity of a mouse monoclonal antibody reactive with Cryptococcus neoformans capsular polysaccharide. Infect. Immun. 55:742-748.
25. Eckert, T. F., and T. R. Kozel. 1987. Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide. Infect. Immun. 55:1895-1899.
26. Evans, E. E. 1950. The antigenic composition of Cryptococcus neoformans. I. A serologic classification by means of the capsular and agglutination reactions. J. Immunol. 64:423-430.
27. Fromtling, R. A, H. J. Shadomy, and E. S. Jacobson. 1982. Decreased virulence in stable, acapsular mutants of Cryptococcus neoformans. Mycopathologia 79:23-29.
28. Gade, W., S. W. Hinnefeld, L. S. Babcock, P. Gilligan, W. Kelly, K. Wait, D. Greer, M. Pinilla, and R. Kaplan. 1991. Comparison of the Premier cryptococcal antigen enzyme immunoassay and the latex agglutination assay for detection of cryptococcal antigens. J. Clin. Microbiol. 29:1616-1619.
29. Ikeda, R., A. Nishikawa, T. Shinoda, and Y. Fukazawa. 1985. Chemical characterization of capsular polysaccharide from Cryptococcus neoformans serotype A-D. Microbiol. Immunol. 29:981-991.
30. Ikeda, R., S. Nishimura, A. Nishikawa, and T. Shinoda. 1996. Production of agglutinating monoclonal antibody against antigen 8 specific for Cryptococcus neoformans serotype D. Clin. Diagn. Lab. Immunol. 3:89-92.
31. Ikeda, R., T. Shinoda, Y. Fukazawa, and L. Kaufman. 1982. Antigenic characterization of Cryptococcus neoformans serotypes and its application to serotyping of clinical isolates. J. Clin. Microbiol. 16:22-29.
32. Kaplan, M. H., P. P. Rosen, and D. Armstrong. 1977. Cryptococcosis in a cancer hospital: clinical and pathological correlates in forty-six patients. Cancer 39:2265-2274.
33. Kiska, D. L., D. R. Orkiszewski, D. Howell, and P. H. Gilligan. 1994. Evaluation of new monoclonal antibody-based latex agglutination test for detection of cryptococcal polysaccharide antigen in serum and cerebrospinal fluid. J. Clin. Microbiol. 32:2309-2311.
34. Kovacs, J. A., A. A. Kovacs, M. Polis, W. C. Wright, V. J. Gill, C. U. Tuazon, E. P. Gelmann, H. C. Lane, R. Longfield, G. Overturf, A. M. Macher, A. S. Fauci, J. E. Parrillo, J. E. Bennett, and H. Masur. 1985. Cryptococcosis in the acquired immunodeficiency syndrome. Ann. Intern. Med. 103:533-538.
35. Kozel, T. 1996. Abstracts of the Third International Conference on Cryptococcus and Cryptococcosis, Paris, France.
36. Kwon-Chung, K.-J., and J. E. Bennett. 1992. Medical mycology, p. 397-446. The Williams & Wilkins Co., Baltimore, Md.
37. Mukherjee, J., G. Nussbaum, M. D. Scharff, and A. Casadevall. 1995. Protective and non-protective monoclonal antibodies to Cryptococcus neoformans originating from one B-cell. J. Exp. Med. 181:405-409.
38. Mukherjee, J., L-A. Pirofske, M. D. Scharff, and A. Casadevall. 1993. Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection. Proc. Natl. Acad. Sci. USA 90:3636-3640.
39. Mukherjee, J., M. D. Scharff, and A. Casadevall. 1992. Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect. Immun. 60:4534-4541.
40. Mukherjee, J., L. S. Zuckier, M. D. Scharff, and A. Casadevall. 1994. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B. Antimicrob. Agents Chemother. 38:580-587.
41. Mukherjee, S., S. C. Lee, and A. Casadevall. 1994. Antibodies to Cryptococcus neoformam glucuronoxylomannan enhance antifungal activity of human macrophages. Infect. Immun. 63:573-579.
42. Otteson, E. W., W. H. Welch, and T. R. Kozel. 1994. Protein-polysaccharide interactions: a monoclonal antibody specific for the capsular polysaccharide of Cryptococcus neoformans. J. Biol. Chem. 269:1858-1864.
43. Pettoello-Mantovani, M., A. Casadevall, T. R. Kollmann, A. Rubinstein, and H. Goldstein. 1992. Enhancement of HIV-1 infection by the capsular polysaccharide of Cryptococcus neoformans. Lancet 339:21-23.
44. Sanford, J. E., D. M. Lupan, A. M. Schlageter, and T. R. Kozel. 1990. Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide. Infect. Immun. 58:1919-1923.
45. Shimizu, R. Y., D. H. Howard, and M. N. Clancy. 1986. The variety of Cryptococcus neoformans in patients with AIDS. J. Infect. Dis. 154:1042.
46. Skelton, M. A., R. Cherniak, L. Poppe, and H. van Halbeek. 1991. Structure of the de-O-acetylated glucuronoxylomannan from Cryptococcus neoformans serotype D, as determined by 2D NMR spectroscopy. Magn. Reson. Chem. 29:786-793.
47. Spiropulu, C., R. A. Eppard, E. Otteson, and T. R. Kozel. 1989. Antigenic variation within serotypes of Cryptococcus neoformans detected by monoclonal antibodies specific for the capsular polysaccharide. Infect. Immun. 57: 3240-3242.
48. Temstet, A., P. Roux, J. Poirot, O. Ronin, and F. Dromer. 1992. Evaluation of monoclonal antibody-based latex agglutination test for diagnosis of cryptococcosis: comparison with two tests using polyclonal antibodies. J. Clin. Microbiol. 30:2544-2550.
49. Todaro-Luck, F., E. Reiss, R. Cherniak, and L. Kaufman. 1989. Characterization of Cryptococcus neoformans capsular glucuronoxylomannan polysaccharide with monoclonal antibodies. Infect. Immun. 57:3882-3887.
50. Turner, S. H., and R. Cherniak. 1991. Glucuronoxylomannan of Cryptococcus neoformans serotype B: structural analysis by gas-liquid chromatography-mass spectrometry and C-nuclear magnetic resonance spectroscopy. Carbohydr. Res. 211:103-116.
51. Turner, S. H., and R. Cherniak. 1991. Multiplicity in the structure of the glucuronoxylomannan of Cryptococcus neoformans, p. 123-142. In J. P. Latge and D. Boucias (ed.), Fungal cell wall and immune response. Springer-Verlag, Berlin, Germany.
52. Turner, S. H., R. Cherniak, E. Reiss, and K. J. Kwon-Chung. 1992. Structural variability in the glucuronoxylomannan of Cryptococcus neoformans serotype A isolates determined by 13C NMR spectroscopy. Carbohydr. Res. 233:205-218.
53. Wilson, D. E., J. E. Bennett, and J. W. Bailey. 1968. Serologic grouping of Cryptococcus neoformans. Proc. Soc. Exp. Biol. Med. 127:820-823.
54. Yuan, R., A. Casadevall, G. Spira, and M. D. Scharff. 1995. Isotype switching from IgG3 to IgG1 converts a nonprotective murine antibody to Cryptococcus neoformans into a protective antibody. J. Immunol. 154:1810-1816.